Research Grade Sotigalimab
TheFDAhasgrantedanorphandrugdesignationtosotigalimab (APX005M) asapotentialtherapeuticoptionforpatientswithsofttissuesarcoma, accordingtoannouncementfromApexigenInc., thedrugdeveloper. Anovel, humanizedmonoclonalantibody, sotigalimabwasdesignedstimulateantitumorimmuneresponseandtotargetCD40, whichisakeyco-stimulatoryreceptorthatservestoactivateinnateandadaptiveimmunesystems.WhensotigalimabbindstoCD40onantigen-presentingcells, itinducesamultifacetedimmuneresponsethatbringsseveralcomponentsoftheimmunesystemtogethertoattackthecancer.
Product Specifications
Product Name Alternative
APX005M, APX-005, APX-005-M, APX-005M, CAS:2305607-45-6
Expression System
Mammalian Cells
Host
Humanized
Target
Tumornecrosisfactorreceptorsuperfamilymember5, B-cellsurfaceantigenCD40, Bp50, CD40Lreceptor, TNFRSF5, CDw40, CD40
Clonality
Monoclonal
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Purification
Protein A/G purified from cell culture supernatant.
Concentration
1.7mg/ml
Endotoxin
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Form
Liquid
Buffer
0.01M PBS, pH7.4.
Storage Conditions
Notes
For research use only. Not suitable for clinical or therapeutic use.
Buffer pH
0.01M PBS, pH7.4.
Species
Human
Isotype
IgG1-Kappa
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
